

PATENT
674525-2002

7. (Currently amended) [[A]] The method according to claim 6, wherein the immunosuppressive cytokine is selected from the group consisting of IL-4, IL-10, IL-13, TGF- β and FLT3 ligand.

8. (Currently amended) The method according to claim 2, any one of claims 1 to 4 wherein the Notch ligand is selected from the group consisting of Serrate, Delta and homologues thereof.

9. (Currently amended) The method according to claim 2, any one of claims 1 to 4 wherein the APC is a dendritic cell.

10. (Currently amended) A method for producing a regulatory lymphocyte or APC having for promoting tolerance to an allergen or antigen, which method comprises incubating a lymphocyte or APC obtained from a human or animal patient with [[a]] the regulatory lymphocyte or APC produced by the method of claim 2 any one of claims 1 to 4.

11. (Currently amended) [[A]] The method according to claim 10, wherein the lymphocyte is for producing ex vivo a T cell having tolerance to an allergen or antigen which method comprises incubating a T cell obtained from a human or animal patient with a cell produced by the method of any one of claims 1 to 4.

12. (Currently amended) A method for suppressing an immune response in a mammal to an allergen or antigen comprising:

a) producing a regulatory lymphocyte by the method of claim 2; and incubating a lymphocyte or APC obtained from a human or animal patient with (i) a composition capable of upregulating expression of Serrate or Delta in the lymphocyte or APC and (ii) the allergen or antigen and

b) administering the regulatory lymphocyte or APC to the mammal, wherein the regulatory lymphocyte suppresses an immune response to the allergen or antigen.

13. (Currently amended) Use of a composition capable of upregulating expression of an endogenous Notch or Notch ligand in an APC or lymphocyte in a A method of producing a regulatory lymphocyte lymphocytes capable of suppressing the activity of other lymphocytes, comprising contacting a lymphocyte with the regulatory lymphocyte produced by the method of claim 2, thereby producing a regulatory lymphocyte.

14-16. (Cancelled)

PATENT
674525-2002

17. (Currently amended) A method of treating a patient suffering from a disease characterized by inappropriate lymphocyte activity, which method comprises administering to the patient a regulatory lymphocyte produced by the method of claim 2 or claim 13 ~~any one of claims 1 to 9.~~

18. (Cancelled)

19. (Currently amended) A method for producing a regulatory lymphocyte or antigen presenting cell (APC) ~~having~~ for promoting tolerance to an allergen or antigen, which method comprises:

a) incubating an antigen presenting cell (APC) ~~a lymphocyte or APC~~ obtained from a human or animal patient with (i) a composition capable of upregulating expression of Serrate or Delta in the ~~lymphocyte and/or~~ APC and (ii) the allergen or antigen, thereby producing a primed APC, wherein the lymphocyte is a T cell and the APC is a dendritic cell, and wherein the composition comprises a polypeptide selected from the group consisting of Noggin, Chordin, Follistatin, Xnr3, FGF and immunosuppressive cytokines; and

b) contacting a lymphocyte with the primed APC, thereby producing a regulatory lymphocyte.

20. (Currently amended) The method of claim 2 or claim 19, wherein the allergen or antigen is selected from the group consisting of myelin basic protein, collagen, insulin, MHC antigens and Der p 1.

21-24. (Cancelled)

25. (Currently amended) The method according to claim 19, ~~any one of claims 21 to 24~~, wherein the composition ~~comprises a substance~~ capable of upregulating expression of Serrate or Delta comprises a substance selected from the group consisting of Notch or a Notch ligand selected from polypeptides and fragments thereof, linear peptides, cyclic peptides, synthetic compounds, and natural compounds, including low molecular weight organic compounds and low molecular weight or inorganic compounds.

26. (Cancelled)

27. (Currently amended) The method according to claim[[26]] 19, wherein the immunosuppressive cytokine is selected from the group consisting of IL-4, IL-10, IL-13, TGF- β and FLT3 ligand.

28. (Cancelled)

PATENT
674525-2002

29. (Cancelled)

30. (Currently amended) A method for producing a regulatory lymphocyte or APC ~~having for promoting~~ tolerance to an allergen or antigen, which method comprises incubating a lymphocyte ~~or APC~~ with the regulatory lymphocyte a lymphocyte or APC produced by the method of claim 19 ~~any one of claims 21 to 24~~.

31. (Cancelled)

32. (Currently amended) A method for suppressing an immune response in a mammal to an allergen or antigen comprising:

a) producing a regulatory lymphocyte by the method of claim 19; and incubating a lymphocyte or APC with (i) a composition capable of upregulating expression of Serrate or Delta in the lymphocyte or APC and (ii) the allergen or antigen and

b) administering the regulatory lymphocyte or APC to the mammal, wherein the regulatory lymphocyte suppresses an immune response to the allergen or antigen.

33. (Cancelled)

34. (Cancelled)